论文部分内容阅读
目的探讨微刺激联合拮抗剂方案进行体外受精-胚胎移植(in vitro fertilization and embryotransfer,IVF-ET)在卵巢低反应患者的应用价值。方法对76例卵巢低反应患者采用微刺激联合拮抗剂方案进行IVF-ET的临床资料进行回顾性分析。结果76例卵巢低反应患者共116个起始周期,9个周期因提前排卵或无卵泡发育而取消,周期取消率为7.76%;共完成107个取卵周期,74个移植周期。获卵总数为251枚,平均获卵(2.69±1.62)枚。获取成熟卵母细胞204枚,总受精176枚,正常受精163枚,总受精率为70.12%,正常受精率为64.94%。卵裂163枚,卵裂率为92.61%。生化妊娠1例,临床妊娠12例,取卵周期临床妊娠率为11.21%,移植周期临床妊娠率为16.21%,起始周期临床妊娠率为10.34%。胚胎着床率为11.29%。结论微刺激联合拮抗剂方案可以作为使用常规控制性超排卵(controlled ovarian hyperstimulation,COH)方案进行过IVF-ET治疗失败的卵巢低反应者的另一有效治疗方案。
Objective To investigate the value of in vitro fertilization and embryo transfer (IVF-ET) in patients with low ovarian response. Methods A retrospective analysis was performed on the clinical data of 76 cases of ovarian low response patients treated with micro-stimulation combined with antagonist for IVF-ET. Results A total of 116 initial cycles were observed in 76 patients with low ovarian response. Nine cycles were canceled due to anovulation or follicular development. The rate of cancellation was 7.76%. A total of 107 cycles of oocyte retrieval and 74 cycles of transplantation were completed. The total number of oops was 251, with an average of 2.69 ± 1.62 eggs. Obtained 204 mature oocytes, total fertilization 176, normal fertilization 163, the total fertilization rate was 70.12%, the normal fertilization rate was 64.94%. 163 cleavages, cleavage rate was 92.61%. 1 case of biochemical pregnancy, 12 cases of clinical pregnancy, clinical pregnancy rate of ovulation cycle was 11.21%, clinical pregnancy rate of transplantation cycle was 16.21%, clinical pregnancy rate of initial cycle was 10.34%. Embryo implantation rate was 11.29%. Conclusions The micro stimulant co-antagonist regimen can be used as another effective treatment for those with hypoplasia who have failed IVF-ET therapy using the controlled ovarian hyperstimulation (COH) regimen.